🇺🇸 FDA
Pipeline program

KAI-9531

K9531-3107

Phase 3 small_molecule active

Quick answer

KAI-9531 for Obesity is a Phase 3 program (small_molecule) at Kailera Therapeutics with 3 ClinicalTrials.gov record(s).

Program details

Company
Kailera Therapeutics
Indication
Obesity
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials